CS223879B2 - Method of gaining natural terpenes with antipsoriatic effect - Google Patents

Method of gaining natural terpenes with antipsoriatic effect Download PDF

Info

Publication number: CS223879B2
Authority: CS; Czechoslovakia
Prior art keywords: polypodium; hexane; solution; ethanol; residue
Prior art date: 1978-05-24

Application number

CS793543A

Other languages

Czech (cs)

English (en)

Inventor

Francisco R A Salgado

De Alvarado Blanca Z N Rivera

Original Assignee

Conrad Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-05-24

Filing date

1979-05-23

Publication date

1983-11-25

1979-05-23 Application filed by Conrad Ltd filed Critical Conrad Ltd

1983-11-25 Publication of CS223879B2 publication Critical patent/CS223879B2/cs

Links

230000002682 anti-psoriatic effect Effects 0.000 title claims abstract description 7
238000000034 method Methods 0.000 title abstract description 11
150000003505 terpenes Chemical class 0.000 title abstract description 6
235000007586 terpenes Nutrition 0.000 title abstract description 6
238000001704 evaporation Methods 0.000 claims abstract description 12
239000002904 solvent Substances 0.000 claims abstract description 8
241000487005 Phlebodium decumanum Species 0.000 claims abstract description 6
241000393483 Dryopteris crassirhizoma Species 0.000 claims abstract description 4
229940075984 polypodium leucotomos Drugs 0.000 claims abstract description 4
241001518143 Polypodium <fern> Species 0.000 claims abstract description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 77
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 24
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
239000002244 precipitate Substances 0.000 claims description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
239000000463 material Substances 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
238000005406 washing Methods 0.000 claims description 8
239000000284 extract Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
230000008020 evaporation Effects 0.000 claims description 6
239000008346 aqueous phase Substances 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
239000011521 glass Substances 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
238000004140 cleaning Methods 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 4
239000002184 metal Substances 0.000 claims description 4
239000000047 product Substances 0.000 claims description 4
241000244324 Polypodium aureum Species 0.000 claims description 3
239000013078 crystal Substances 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
239000003208 petroleum Substances 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
241000592274 Polypodium vulgare Species 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
238000010924 continuous production Methods 0.000 claims description 2
238000002425 crystallisation Methods 0.000 claims description 2
238000005520 cutting process Methods 0.000 claims description 2
239000012454 non-polar solvent Substances 0.000 claims description 2
229920001296 polysiloxane Polymers 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
238000005259 measurement Methods 0.000 claims 1
230000008569 process Effects 0.000 abstract description 6
241000196324 Embryophyta Species 0.000 abstract description 3
241001362840 Serpocaulon triseriale Species 0.000 abstract description 3
241000723185 Cyathea Species 0.000 abstract description 2
241001624848 Phlebodium Species 0.000 abstract 1
241001625037 Phlebodium aureum Species 0.000 abstract 1
238000000638 solvent extraction Methods 0.000 abstract 1
239000000243 solution Substances 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
201000004681 Psoriasis Diseases 0.000 description 6
241000238876 Acari Species 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000000605 extraction Methods 0.000 description 5
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000001185 psoriatic effect Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZHDRLFGZQZCZKX-BQOUFORSSA-N Fernene Chemical compound CC1(C)CCC[C@]2(C)C3=CC[C@@]4(C)[C@@H]5CC[C@H](C(C)C)[C@@]5(C)CC[C@]4(C)[C@H]3CC[C@H]21 ZHDRLFGZQZCZKX-BQOUFORSSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000006193 liquid solution Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
235000012431 wafers Nutrition 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000005352 clarification Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000985694 Polypodiopsida Species 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
-1 italek Chemical compound 0.000 description 1
239000003350 kerosene Substances 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
206010033898 parapsoriasis Diseases 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000009967 tasteless effect Effects 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Natural Medicines & Medicinal Plants (AREA)
Dermatology (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Compounds Of Unknown Constitution (AREA)
Peptides Or Proteins (AREA)

CS793543A 1978-05-24 1979-05-23 Method of gaining natural terpenes with antipsoriatic effect CS223879B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES470204A ES470204A1 (es)	1978-05-24	1978-05-24	Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica

Publications (1)

Publication Number	Publication Date
CS223879B2 true CS223879B2 (en)	1983-11-25

Family

ID=8476164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS793543A CS223879B2 (en)	1978-05-24	1979-05-23	Method of gaining natural terpenes with antipsoriatic effect

Country Status (34)

Country	Link
JP (1)	JPS59486B2 (es)
AR (1)	AR226999A1 (es)
AT (1)	AT366260B (es)
AU (1)	AU529300B2 (es)
BE (1)	BE872718A (es)
BG (1)	BG34449A3 (es)
CA (1)	CA1122589A (es)
CH (1)	CH642039A5 (es)
CS (1)	CS223879B2 (es)
CU (1)	CU35086A (es)
DE (1)	DE2847836C3 (es)
DK (1)	DK211879A (es)
EG (1)	EG14353A (es)
ES (1)	ES470204A1 (es)
FI (1)	FI64892C (es)
FR (1)	FR2426471A1 (es)
GB (1)	GB2022094B (es)
GR (1)	GR65351B (es)
HU (1)	HU180710B (es)
IE (1)	IE48415B1 (es)
IL (1)	IL57377A (es)
IT (1)	IT7919644A0 (es)
LU (1)	LU81315A1 (es)
MA (1)	MA18443A1 (es)
MX (1)	MX5537E (es)
NL (1)	NL7904063A (es)
NO (1)	NO791704L (es)
NZ (1)	NZ190535A (es)
PL (1)	PL126926B1 (es)
PT (1)	PT68719A (es)
SE (1)	SE7903761L (es)
SU (1)	SU995700A3 (es)
YU (1)	YU121579A (es)
ZA (1)	ZA792540B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES490293A0 (es) *	1980-04-02	1981-04-16	Conrad Ltd	Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae.
EP0503208A1 (en) *	1991-03-08	1992-09-16	Maracuyama International, S.A.	Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2088770B1 (es) *	1995-02-23	1997-03-16	Esp Farmaceuticas Centrum Sa	Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
ATE222112T1 (de) *	1994-05-06	2002-08-15	Esp Farmaceuticas Centrum Sa	Pharmazeutische zusammensetzung enthaltend farnextrakt(e) zur behandlung von neurodegenerativen krankheiten.
ES2068163B1 (es) *	1994-05-06	1995-09-01	Esp Farmaceuticas Centrum Sa	Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
RU2124363C1 (ru) *	1996-08-23	1999-01-10	Общество с ограниченной ответственностью "Сибирский богатырь"	Способ лечения дерматологических заболеваний
US6228366B1 (en) *	1998-07-29	2001-05-08	Helsint, S.A.L.	Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3395223A (en) *	1965-05-13	1968-07-30	Carter Wallace	Fern extract for treating gastric ulcers
JPS5464871A (en) *	1977-10-31	1979-05-25	Nippon Electric Co	Device for firing discharge lamp
ES471572A1 (es) *	1978-07-07	1979-01-16	Conrad Ltd	Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica

1978
- 1978-05-24 ES ES470204A patent/ES470204A1/es not_active Expired
- 1978-10-11 AR AR274039A patent/AR226999A1/es active
- 1978-10-12 GR GR57430A patent/GR65351B/el unknown
- 1978-10-25 CA CA314,254A patent/CA1122589A/en not_active Expired
- 1978-10-30 PT PT68719A patent/PT68719A/pt unknown
- 1978-11-03 DE DE2847836A patent/DE2847836C3/de not_active Expired
- 1978-12-13 BE BE192279A patent/BE872718A/xx not_active IP Right Cessation
1979
- 1979-01-26 IT IT7919644A patent/IT7919644A0/it unknown
- 1979-04-05 MX MX797853U patent/MX5537E/es unknown
- 1979-04-27 SE SE7903761A patent/SE7903761L/xx not_active Application Discontinuation
- 1979-05-21 MA MA18637A patent/MA18443A1/fr unknown
- 1979-05-22 FI FI791616A patent/FI64892C/fi not_active IP Right Cessation
- 1979-05-22 AT AT0375279A patent/AT366260B/de not_active IP Right Cessation
- 1979-05-22 CH CH477679A patent/CH642039A5/de not_active IP Right Cessation
- 1979-05-22 EG EG309/79A patent/EG14353A/xx active
- 1979-05-23 SU SU792771805A patent/SU995700A3/ru active
- 1979-05-23 YU YU01215/79A patent/YU121579A/xx unknown
- 1979-05-23 HU HU79CO370A patent/HU180710B/hu unknown
- 1979-05-23 NO NO791704A patent/NO791704L/no unknown
- 1979-05-23 IL IL57377A patent/IL57377A/xx unknown
- 1979-05-23 FR FR7913216A patent/FR2426471A1/fr active Granted
- 1979-05-23 ZA ZA792540A patent/ZA792540B/xx unknown
- 1979-05-23 PL PL1979215804A patent/PL126926B1/pl unknown
- 1979-05-23 LU LU81315A patent/LU81315A1/xx unknown
- 1979-05-23 NZ NZ190535A patent/NZ190535A/xx unknown
- 1979-05-23 BG BG043706A patent/BG34449A3/xx unknown
- 1979-05-23 DK DK211879A patent/DK211879A/da not_active Application Discontinuation
- 1979-05-23 CU CU7935086A patent/CU35086A/es unknown
- 1979-05-23 CS CS793543A patent/CS223879B2/cs unknown
- 1979-05-23 NL NL7904063A patent/NL7904063A/xx not_active Application Discontinuation
- 1979-05-24 JP JP54064870A patent/JPS59486B2/ja not_active Expired
- 1979-05-24 AU AU47381/79A patent/AU529300B2/en not_active Ceased
- 1979-05-24 GB GB7918175A patent/GB2022094B/en not_active Expired
- 1979-08-08 IE IE974/79A patent/IE48415B1/en unknown

Also Published As

Publication number	Publication date
DK211879A (da)	1979-11-25
NO791704L (no)	1979-11-27
ES470204A1 (es)	1979-01-01
JPS59486B2 (ja)	1984-01-07
NZ190535A (en)	1981-10-19
MX5537E (es)	1983-09-27
FR2426471A1 (fr)	1979-12-21
SE7903761L (sv)	1979-11-25
AR226999A1 (es)	1982-09-15
PL215804A1 (es)	1980-03-24
BG34449A3 (en)	1983-09-15
CA1122589A (en)	1982-04-27
IT7919644A0 (it)	1979-01-26
GB2022094A (en)	1979-12-12
IL57377A (en)	1983-12-30
IL57377A0 (en)	1979-09-30
NL7904063A (nl)	1979-11-27
JPS54154799A (en)	1979-12-06
DE2847836A1 (de)	1979-11-29
ZA792540B (en)	1980-09-24
PL126926B1 (en)	1983-09-30
FR2426471B1 (es)	1983-07-29
IE48415B1 (en)	1985-01-09
AU4738179A (en)	1979-11-29
GB2022094B (en)	1983-04-27
HU180710B (en)	1983-04-29
DE2847836C3 (de)	1981-12-17
FI64892C (fi)	1984-02-10
ATA375279A (de)	1981-08-15
FI64892B (fi)	1983-10-31
PT68719A (en)	1978-11-01
GR65351B (en)	1980-08-18
MA18443A1 (fr)	1979-12-31
IE790974L (en)	1979-11-24
SU995700A3 (ru)	1983-02-07
LU81315A1 (fr)	1979-09-11
CH642039A5 (de)	1984-03-30
AU529300B2 (en)	1983-06-02
FI791616A7 (fi)	1979-11-25
DE2847836B2 (de)	1981-01-15
AT366260B (de)	1982-03-25
YU121579A (en)	1983-09-30
BE872718A (fr)	1979-03-30
EG14353A (en)	1983-12-31
CU35086A (en)	1981-12-04

Publication	Publication Date	Title
EP0210785B1 (en)	1990-09-26	Process for obtaining proanthocyanidine a2, pharmaceutical compositions and their therapeutic use
JPS6059237B2 (ja)	1985-12-24	シソ科植物からの有効物質
EP0036663B1 (de)	1984-09-12	Oxiranbuttersäure-Derivate, ihre Herstellung und Verwendung, sowie diese enthaltende Arzneimittel
US5430054A (en)	1995-07-04	Preparation methods of diterpene lactone compounds and application of the same to antifertility
CA1106285A (en)	1981-08-04	Process for obtaining a natural polar fraction having anti-psoriatic activity
CS223879B2 (en)	1983-11-25	Method of gaining natural terpenes with antipsoriatic effect
DD210687A5 (de)	1984-06-20	Verfahren zur herstellung von (+)-cyanidan-3-ol-derivaten
US4221790A (en)	1980-09-09	Substituted 2,2-dioxo-1,2,3-benzoxathiazines
DE2632118B2 (de)	1979-02-01	Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel
US3869476A (en)	1975-03-04	Therapeutically active isovaleric acid esters
US4847246A (en)	1989-07-11	Antiviral compositions derived from fireflies and their methods of use
EP0541780A1 (en)	1993-05-19	ANTINEOPLASM CHEMOTHERAPIC SUBSTANCE OF PLANT ORIGIN, HAVING HIGH SELECTIVITY AND VERY REDUCED TOXICITY, AND PROCESS FOR PREPARING THE SAME.
US4094988A (en)	1978-06-13	Method of treating gastric ulcers using 5,6-dihydro-1,4-dithiinoxides
JPS58150584A (ja)	1983-09-07	クワノン化合物
JPH0285211A (ja)	1990-03-26	新規フェネチルアルコール配糖体および免疫抑制剤
US4740521A (en)	1988-04-26	Saudin, a novel hypoglycemic agent
JPS6165895A (ja)	1986-04-04	新規クアシノイド化合物及びその製法
US3873699A (en)	1975-03-25	Pharmacologically active substances isolated from {8 cadia ellisiana {b
US3740426A (en)	1973-06-19	Pharmacologically effective substance for lowering blood pressure andprocess for isolating it from cabucala madagascariensis
JPH0892118A (ja)	1996-04-09	狼毒に含まれる抗癌および抗ウィルス性成分の採取法および使用法
JPH0228597B2 (es)	1990-06-25
JPS6172719A (ja)	1986-04-14	抗高脂血症剤
DE2713506A1 (de)	1977-10-13	Ester der 2- eckige klammer auf 4-(4-chlorbenzoyl)-phenoxy eckige klammer zu -2-methylpropionsaeure mit bis-(hydroxyalkylthio)-alkanen und sie enthaltende arzneimittel
JPS63227584A (ja)	1988-09-21	新規フラボン化合物
JPS61227575A (ja)	1986-10-09	（４ｓ，５ｓ）−（＋）−ゲルマクロン４，５−エポキサイド、その製造法及び抗潰瘍治療剤